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Abstract
Saccharomyces cerevisiae is the most well characterized eukaryote, the preferred microbial cell factory for the largest
industrial biotechnology product (bioethanol), and a robust commerically compatible scaffold to be exploitted for diverse
chemical production. Succinic acid is a highly sought after added-value chemical for which there is no native pre-disposition
for production and accmulation in S. cerevisiae. The genome-scale metabolic network reconstruction of S. cerevisiae enabled
in silico gene deletion predictions using an evolutionary programming method to couple biomass and succinate
production. Glycine and serine, both essential amino acids required for biomass formation, are formed from both glycolytic
and TCA cycle intermediates. Succinate formation results from the isocitrate lyase catalyzed conversion of isocitrate, and
from the a-keto-glutarate dehydrogenase catalyzed conversion of a-keto-glutarate. Succinate is subsequently depleted by
the succinate dehydrogenase complex. The metabolic engineering strategy identified included deletion of the primary
succinate consuming reaction, Sdh3p, and interruption of glycolysis derived serine by deletion of 3-phosphoglycerate
dehydrogenase, Ser3p/Ser33p. Pursuing these targets, a multi-gene deletion strain was constructed, and directed evolution
with selection used to identify a succinate producing mutant. Physiological characterization coupled with integrated data
analysis of transcriptome data in the metabolically engineered strain were used to identify 2nd-round metabolic engineering
targets. The resulting strain represents a 30-fold improvement in succinate titer, and a 43-fold improvement in succinate
yield on biomass, with only a 2.8-fold decrease in the specific growth rate compared to the reference strain. Intuitive genetic
targets for either over-expression or interruption of succinate producing or consuming pathways, respectively, do not lead
to increased succinate. Rather, we demonstrate how systems biology tools coupled with directed evolution and selection
allows non-intuitive, rapid and substantial re-direction of carbon fluxes in S. cerevisiae, and hence show proof of concept
that this is a potentially attractive cell factory for over-producing different platform chemicals.
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Introduction
Industrial biotechnology is a promising alternative to traditional
petrochemical production of chemicals focused on developing
commercially sustainable and environmentally favorable processes
[1]. Metabolic engineering, the directed genetic modification of
cellular reactions, aims to change the metabolic architecture of
microorganisms to efficiently produce target chemicals [2].
Although examples of metabolic engineering successes exist, there
has yet to be developed a pipeline where preferred industrial hosts
are rapidly engineered to produce a non-native accumulating
target metabolite. Recent advances in systems biology enabled in
silico genome-scale metabolic network reconstructions to guide
metabolic engineering strategies [1], [3], [4]. Here we describe
a pipeline where a microbial strain was constructed, physiologi-
cally characterized, and genomic tools were used to verify the
predictions. An essential part of the pipeline is the use of genome-
scale metabolic models for initial guiding of the metabolic
engineering, which has been shown to be useful also in earlier
studies [3], [5], [6]. This approach was repeated and comple-
mented with traditional directed evolution and selection until
a proof of concept microbial cell factory was reached. This
pipeline resulted in the construction of a non-intuitive Saccharomyces
cerevisiae cell factory over-producing succinic acid, a building block
chemical.
S. cerevisiae is the most well characterized eukaryote and is
unique in its broad application as an industrial production
platform for a large portfolio of products including foods and
beverages, bioethanol, vaccines, and therapeutic proteins [1].
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Many systems biology tools, including high-throughput genome
sequencing, transcriptional profiling, metabolomics, carbon flux
estimations, proteomics, in silico genome-scale modeling, and
bioinformatics driven data integration were first applied to S.
cerevisiae [4]. Metabolic engineering has benefited from each of
these tools; however, relatively few examples exist where
cumulative integration has resulted in a generalized pipeline, in
particular for the production of a target compound that the
organism does not accumulate significantly naturally.
Succinic acid, systematically identified as butanedioic acid
(pKa1 4.21, pKa2 5.72), is a value-added chemical building block,
with an estimated 15,000 t/year world-wide demand predicted to
expand to commodity chemical status with 270,000 t/year [7], [8]
representing a potential .2 billion USD annual market. There are
several elegant examples of bio-based production of succinate in
Anaerobiospirillium succiniciproducens, Actinobacillus succinogenes, Succini-
vibrio dextrinosolvens, Corynebacterium glutanicum, Prevotella ruminocola,
a recently isolated bacterium from bovine rumen, Mannheimia
succiniciproducens, and a metabolically engineered succinic acid
over-producing E. coli [7], [8], [9], [10], [11], [12]. All of the hosts
described are prokayotic that grow at neutral pH, and conse-
quently secrete the salt, succinate, requiring a cost-intensive
acidification and precipitation to reach the desired succinic acid.
This concern is not specific to succinic acid production, but rather
universal when considering organic acid producing microbial cell
factories [13]. S. cerevisiae represents a well-established, generally
regarded as safe, robust, scalable (1L to 100,000L) industrial
production host capable of growth on diverse carbon sources,
chemically defined medium, both aerobic and anaerobic, and
a wide pH operating range (3.0–6.0). Unlike the hosts described
above, succinate is not naturally produced by S. cerevisiae; but as
there are many factors of importance for the choice of a microbial
cell factory it is not uncommon that the chosen cell factory lacks
predisposition to produce the target chemical of choice [14]. As
industrial biotechnology progresses forward, and the concept of
biorefineries are gaining increased importance, platform technol-
ogies including microbial cell factories that can plug-and-play into
existing infrastructures must be developed [15]. S. cerevisiae is
uniquely positioned as a platform technology as it is already used
widely for bioethanol production, but also because of the extensive
library of genetic engineering tools, a very well annotated genome,
many omics tools available, and well established complimentary
approaches for directed evolution and selection. We therefore
addressed the question whether it is possible to metabolically
engineer S. cerevisiae such that the carbon fluxes are redirected
towards succinic acid, and hereby establish proof-of-concept of
using this yeast as a general cell factory platform for chemical
production. The final strain emerging from this study requires
significant further metabolic engineering and process development
prior to consideration for commercialization, but the approach
and integration of methods demonstrated supports the hypothesis
that highly regulated central carbon metabolism in ideal pro-
duction hosts can be reconfigured to produce target chemicals,
relatively quickly and with minimal resources.
Results
In the present study, our objective was to evaluate the use of
genome-scale metabolic models for in silico identification of gene
deletion targets. We therefore used results from a previous study
where an evolutionary programming method, termed OptGene,
was developed for identification of deletion targets to couple
biomass formation (or other biological objective function that is
applicable to the organism under question) with the design
objective function, such as yield (or other linear/non-linear
objective) [16]. These results guided the metabolic engineering
strategy described in Figure 1. Glycine, serine, and threonine, all
representing essential amino acids required for biomass formation,
may be formed from both glycolytic and tricarboxylic acid cycle
intermediates. Succinate formation results from the isocitrate
lyase, Icl1p, catalyzed conversion of isocitrate to equimolar
glyoxylate and succinate, and from the a-keto-glutarate de-
hydrogenase complex, Kgd1p/Kgd2p/Lpd1p, catalyzed conver-
sion of a-keto-glutarate to equimolar succinate, with a net
production of CO2, NADH, and ATP. Succinate is subsequently
depleted by the succinate dehydrogenase complex, Sdh1p/Sdh2p/
Sdh3p/Sdh4p to equimolar fumarate with the net production of
protonated ubiquinone. The metabolic engineering strategy
identified by OptGene included deletion of the primary succinate
consuming reaction encoded by Sdh3 (cytochrome b subunit of the
succinate dehydrogenase complex, essential for function), and
interruption of glycolysis derived serine by deletion of 3-
phosphoglycerate dehydrogenase, Ser3p/Ser33p (isoenzymes).
The remaining pathway for serine synthesis must originate from
glycine, and glycine synthesis is largely derived from the
alanine:pyruvate aminotransferase, Agx1p, converting glyoxylate
and alanine to glycine and pyruvate. With this strategy, glycine
and serine biomass requirements are directly coupled to succinate
formation via the glyoxylate cycle. Substantial succinate accumu-
lation (defined as .0.1 g L21) in the culture broth is not observed
in wild-type S. cerevisiae, and deletion of sdh3 has not resulted in
appreciable succinate accumulation [17]; a conclusion also found
by chemical inhibition of the succinate dehydrogenase complex
with titration of malonate (Figure S1), a chemical inhibtor of this
complex [18].
The mutant resulting from the in silico strategy, referred to as 8D
(Dsdh3 Dser3 Dser33), required supplementation with 500 mg L21
glycine to be able to grow. When evaluated in well controlled,
aerobic, batch stirred tank reactors supplemented with 20 g L21
glucose in chemically defined medium, it exhibited a 13-fold
improvement in succinate secreted titer (0.03 v 0.40 g L21), 14-
fold improvement in succinate biomass yield (0.01 v 0.14 g-
succinate g-biomass21), and a modest 33% reduction in the
specific growth rate. Thus, the in silico guided metabolic
engineering strategy was shown to work, representing a proof-of-
concept of the use of model guided metabolic engineering.
However, in order to obtain a protothropic strain directed
evolution was employed to screen and select for 8D mutants that
did not require glycine supplementation. Specifically, six consec-
utive shake flask cultivations in media supplemented with de-
creasing concentrations of glycine, from an initial 500 mg L21 to
0 mg L21 (see Figure 2) were performed. The resulting strain
demonstrated a 7.7-fold improvement in succinate yield on
biomass (0.09 v 0.69 g-succinate g-biomass21), strongly suggesting
the direct coupling of glycine formation from glyoxylate and
succinate formation. The resulting strain had a relatively low
specific growth rate, 0.03 h21, and was therefore subsequently
cultivated in shake flasks and transferred across six shake flasks
(only first three shake flasks shown in Figure 2) to improve the
specific growth rate. Finally, a specific growth rate of 0.14 h21 was
reached, however, resulting in a decreased succinate yield on
biomass (0.69 v 0.27 g-succinate g-biomass21). The final strain,
referred to as 8D Evolved, was shown to exhibit a 60-fold
improvement in biomass coupled succinate production (0.01 v
0.30 g-succinate g-biomass21), and 20-fold improvement in
succinate titer (0.03 v 0.60 g L21) relative to the reference strain
when grown in aerobic batch cultivations.
Succinic Acid Cell Factory
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To investigate the apparent decoupling of succinate coupled
biomass formation, and potentially identify second-round meta-
bolic engineering strategies, the transcriptome was measured in
aerobic, glucose-limited, mid-exponential phase grown batch
cultivations of 8D Evolved and the reference strain. Continous
cultivations, both carbon-limited and nitrogen-limited chemostats
were attempted with the 8D Evolved mutant; however, in both
cases steady-state was not reached and wash-out occured, even at
relatively low dilution rates (D= 0.03 h21 compared to
mmax = 0.14 h21). It was expected that 8D Evolved would not
support cultivation in carbon-limited continuous culture due to the
down-regulation of the TCA cycle (Dsdh3), and consequently,
reduced capacity for respiratory metabolism and oxidative
phosphorylation. Therefore, batch cultivations were employed
acknowledging the significant differences in specific growth rate
(0.33 v 0.13 h21), and glucose uptake rate (90 v 26 C-mmol g-
DCW21 h21), while maintaining relatively similar biomass yields
(0.18 v 0.19 C-mol biomass C-mol glucose21).
Several studies have shown that significant differences in specific
growth rate directly impact transcriptome interpretation, with
anywhere between 268 and 2400 genes classified as potentially
growth-related [19], [20], [21]. Previously generated continuous
cultivation transcriptome data for both carbon-limited (glucose,
respiratroy growth) and nitrogen-limited (ammonium sulfate,
respiro-fermentative growth) conditions at dilution rates of 0.03,
0.1, and 0.2 h21 were therefore used to identify statistically
differentially expressed growth-related genes [21]. A total of 6 and
7 differentially expressed genes were identified within the carbon-
limited and nitrogen-limited data sets as being growth-related (p-
valueB-H,0.1, n = 3 at each dilution rate), respectively, and a total
of 66 differentially expressed genes were identified when compar-
ing carbon-limited and nitrogen-limited data sets, paired at each
dilution rate (p-valueB-H,0.1, n= 3 at each dilution rate). Of the
total 2406 differentially expressed genes between the 8D Evolved
and reference strain (p-valueB-H,0.01, |log-fold change|.0.5, n = 3
biological replicates, n = 2 DNA microarray duplicates), 36 unique
growth-related genes were identified suggesting that few of the
genes with a significant change in transcription in 8D Evolved are
due to changes in the specific growth rate (see Figure 3). However,
a total of 8 of the top 20 p-valueB-H ranked differentially expressed
genes identified from pair-wise comparison of 8D Evolved and the
reference strain, are growth-related genes (ARO9, SER3, JLP1,
HMALPHA1, ARO10, MFALPHA2, and two uncharacterized
genes, YPL033c and YLR267w).
The top 2000 (there were no metabolic genes in the remaining
406 genes nor were there any biological process annotations
available as determined by gene ontology, and therefore they were
not included in further analysis) differentially expressed genes were
selected for further analysis, and after removal of the 36 growth-
related genes, a list of 1964 genes was submitted for metabolic
Figure 1. Proof-of-concept: Successful metabolic engineering strategy guided by genome-scale metabolic modeling. Panel a shows
the central carbon metabolism of S. cerevisiae, and the model-guided metabolic engineering strategy for succinate over-production. Succinate
production is directly coupled to biomass formation based on three gene deletions: sdh3 (cytochrombe b subunit of succinate dehydrogenase
complex), and ser3/ser33 (3-phosphoglycerate dehydrogenase isoenzymes). The remodeling of central carbon flux towards succinate requires
minimizing the conversion of succinate to fumarate, and forcing the biomass-required amino acids L-glycine and L-serine to be produced from
glyoxylate pools. Production of glyoxylate results from isocitrate conversion by Icl1p, producing equimolar succinate. As the biomass yield increases,
the demand for L-glycine and L-serine increase proportionally, driving biomass-coupled succinate production. Legend: native reactions (blue solid
line), lumped native reactions (blue dashed line), interrupted reactions (red solid line), up-regulated reactions (green solid line). Panel b demonstrates
the proof of concept. The reference strain and genetically engineered mutant strain, 8D, supplemented with 500 mg L21 glycine were physiologically
characterized in 2L well-controlled stirred-tank fermentations. There was a 13.3X improvement in succinate titer.
doi:10.1371/journal.pone.0054144.g001
Succinic Acid Cell Factory
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pathway visualization and characterization to the Expression
Viewer [22] available at the Yeast Genome Database [23] (see
Figure 3). The log-fold change of the 8D Evolved:Reference
expression ratio was mapped onto the metabolic map of S. cerevisiae
strain S288c, version 12.0, composed of 140 pathways, 925
enzymatic reactions, and a total of 675 compounds (see Figure S2).
A total of 315 genes mapped to a specific metabolic pathway on
the expression viewer, with a mean log-fold expression ratio value
of 0.361.3 (n = 315, 6 SD).
Three biologial insights were immediately apparent (see Figure
S2). First, SDH3, SER3, and SER33 had negative log-fold
expression ratios (log-fold change ,-8.0) confirming the gene
deletions targeted in the 8D strain and the maintained low
expression through the directed evolution. Second, when exam-
ining the glycine, serine, and threonine metabolism, AGX1 was 4.3
log-fold change upregulated in the 8D Evolved strain, confirming
significant upregulation of glycine synthesis from glyoxylate pools,
as predicted by the original metabolic engineering strategy.
However, there was no upregulation of SHM2, SHM1, the genes
encoding pathways for L-serine formation from L-glycine pools.
Most surprisingly GLY1, encoding threonine aldolase, was
significantly up-regulated (log-fold change 1.6). In the genome-
scale metabolic network reconstructions of S. cerevisiae iFF708,
iND750, and iIN800, upon which the 8D metabolic engineering
strategy is based, Gly1p encodes the irreversible conversion of
glycine and acetaldehyde to threonine [24], [25], [26], leading to
the prediction that threonine biosynthesis from glycolytic inter-
mediates could be down-regulated, and provided for from glycine
pools. This consequently leads to a greater biomass-coupled drive
for glyoxylate synthesis from isocitrate, yielding equimolar
succinate. Levaraging this over-all strategy, another S. cerevisiae
mutant was constructed, referred to as 20G (Dsdh3, Dser3, Dthr1),
where Thr1p, encoding homoserine kinase that is required for
threonine biosynthesis, was deleted. However, this strain required
threonine supplementation and after several extensive attempts at
adaptive evolution, the threonine auxotrophy persisted, suggesting
the irreversibility of Gly1 was incorrect and the aldolase strongly
favors glycine formation (Figure S3). The significant up-regulation
of Gly1 therefore provides a strong hypothesis for why 8D Evolved
had an attenuation of succinate production, even under increasing
specific growth rate, suggesting a decoupling of biomass coupled
succinate production. It should be noted that in the most recent
update of the genome-scale metabolic reconstruction of S. cerevisiae,
iMM904, the directionality of Gly1 was corrected to now indicate
threonine irreversible conversion to glycine and acetaldehyde [27].
The transcriptome not only provides for a global, rapid, and
quantitative assessment of the predicted in silico metabolic
engineering strategy and insight into the genetic engineering
modifications that result from directed evolution and selection, but
also provides a source for identification of second round metabolic
engineering targets not previously predicted. Several targets were
identified, but of particlar interest was ICL1, encoding isocitrate
lyase, converting isocitrate to glyoxylate and succinate in
equimolar concentrations. All tricarboxylic acid cycle genes are
up-regulated, with the exception of SDH3 (target gene deletion),
and ICL1, providing a clear metaboic engineering target for up-
regulation in the 8D Evolved strain. Therefore, native ICL1 was
PCR amplified and cloned into the 2 mm ori plasmid pRS426CT
containing the strong constitutive TEF1 promoter and CYC1
terminator [28], and then transformed into the reference, 8D, and
8D Evolved strain (strains transformed with the constructed
plasmid pRS426T-ICL1-C are referred to as ‘‘with pICL1’’). All
Figure 2. Metabolic engineering enhanced by directed evolutions. Cell populations were transferred across six shake flask cultures until
a glycine prototroph was isolated. Subsequently, successive cultures were used to select for faster growth. From the final shake flask (SF3) the strain
Evolved 8D was isolated. The succinate yield on biomass is plotted for each shake flask culture, demonstrating a 7.8X increase. The right plot shows
the profile of specific growth rate and succinate yield on biomass for the final selection of faster growing cells.
doi:10.1371/journal.pone.0054144.g002
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strains were evaluated in aerobic, glucose-supplemented batch
fermentations, and only 8D Evolved with pICL1 exhibited
a change in succinate production (see Figure 4). Specifically, the
succinate titer, biomass yield, and glucose yield were 0.90 g L21,
0.43 g-succinate g-biomass21, and 0.05 g-succinate g-glucose21,
respectively, representing a 1.5-fold, 1.4-fold, 1.7-fold improve-
ment over 8D, respectively (see Figure 4).
Discussion
A S. cerevisiae strain capable of succinate production, requiring
redirection of carbon flux from typically produced C2 (ethanol,
acetate) and C3 (glycerol, pyruvate) over-flow metabolites to the
target C4 succinic acid was achieved through metabolic engineer-
ing, requiring integration of systems biology methods and directed
evolution. Clearly, the resulting strain (8D Evolved with pICL1),
while being a successful demonstration of a multi-round metabolic
engineering strategy, still requires significant process development
and further enhancement to compete commercially with existing
bacterial platforms.
The resulting strain, 8D Evolved with pICL1, represents a 30-
fold improvement in succinate titer, and a 43-fold improvement in
succinate yield on biomass, with only a 2.8-fold decrease in the
specific growth rate compared to the reference strain. Despite
success of using simple stoichiometric-based calculations for
driving metabolic engineering, it is interesting to note that
regulatory mechanisms not captured in these models are likely
playing a significant role in the succinate production observed.
The biomass requirements for glycine and serine are 0.290 and
0.185 mmol g-DCW21 [24]. Assuming that all glycine, and all
glycine and serine combined demands are supplied from the
glyoxylate pool, then the theoretical production of succinate would
amount to 0.034 and 0.056 g-succinate g-DCW21, respectively.
The 8D and 8D Evolved strains are producing 0.30 and 0.43 g-
succinate g-biomass21, respectively, suggesting a nearly 8-fold
higher succinate production than required to meet biomass amino
acid demands. A potentially 3rd metabolic engineering target
would be deletion of GLY1 to further minimize alternative
biosynthetic routes of glycine production, thereby isolating all
glycine production to be dependent on glyoxylate formation, and
consequently succinate formation. Yet, it’s clear that any increase
in succinate formation would not be due to biomass requirements,
but rather regulatory (e.g., non-stoichiometric driven) mechan-
isms. Therefore, while the strategy presented and demonstrated
here is likely to be a major component of an over-all succinate
production cell factory, complimentary strategies focussing on the
other major succinate production pathway, TCA cycle, will be
required. Examples of malic acid production, that included
Figure 3. Transcriptome guided metabolic engineering – Analysis. Affymetrix Yeast 2.0 DNA microarrays were used for transcriptome
analysis of each strain cultured in well-controlled glucose batch fermentations. The top 2000 differentially expressed genes had an adjusted
p.value,0.01 and log-fold change (lfc).0.5. A carbon-limited and nitrogen-limited chemostat transcriptome data set using the reference strain,
surveyed at dilution rates (D) of 0.03, 0.1, and 0.2 h21 was used to determine which genes are growth-related under each condition. A total of 36
unique growth-related genes were identified from statistical analysis of each data set and with a total of 8 growth-related genes being among the
top 20 differentially expressed genes between the reference and evolved 8D strain. After removal of the 36 genes, a total of 1964 genes were carried
further for pathway analysis.
doi:10.1371/journal.pone.0054144.g003
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engineering of pyruvate carboxylation (overexpression of PYC2),
oxaloacetate reduction (overexpression of MDH3), and malate
export (functional expression of the non-native SpMAE1), resulted
in a S. cerevisiae strain capable of producing 59 g-malate L21 and
0.42 mol malate mol-glucose21 [29]. A similar approach, re-
quiring yet further engineering and understanding of the reductive
TCA cycle to convert malate to succinate is likely required, but
a major hurdle with this strategy is the conversion of fumarate to
succinate by fumarate reductase which is thermodynamically
favoured in the direction of fumarate.
The transcriptome analysis performed, specifically consider-
ation of continous culture data sets at different dilution rates to
filter growth-related genes was an integral part of identifying the
2nd round of metabolic engineering targets. Although a relatively
small number of growth related genes were identified, they were of
high-value. For example, ARO9 and ARO10, encoding key
enzymatic conversion steps in aromatic amino acid metabolism
may have incorrectly pointed towards tryptophan, tyrosine, and
phenylalanine catabolism or phosphenolpyruvate decarboxylase
activity as metabolic areas of interest for understanding physio-
logical differences between 8D Evolved and the reference strains.
This approach may be extended to future efforts and other
organisms, where continuous cultivation of engineered strains may
not be possible, as in this case, or applied industrially where the
dominant and preferred processing mode is batch.
Furthermore, this work clearly demonstrated that obvious
genetic targets did not result in increased succinate formation.
Specifically, deletion of the primary succinate consuming pathway
(Dsdh3) [17], or constitutive over-expression of one of two of the
primary succinate formation pathways (ICL1) did not result in any
increased succinate production (See Figure S1). It is further
interesting to note that the 8D with pICL1 strain also did not
Figure 4. Summary of succinate microbial cell factory construction. The specific growth rate (1/h), maximum succinate titer (g/L), maximum
succinate yield on biomass (g/g-biomass), and maximum yield on glucose (g/g-glucose) are reported for the reference strain, 8D, 8D evolved, and 8D
evolved with pICL1. A 43-fold improvement in succinate yield on biomass was observed across the full cycle of metabolic engienering that included
in silico guided approaches, directed evolution, and transcriptome based identification of a 2nd round of metabolic engineering targets.
doi:10.1371/journal.pone.0054144.g004
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result in any increased succinate production, but rather only in the
8D Evolved with pICL1 strain. The ability to measure
transcriptome on a strain that underwent targetted genetic
engineering and directed evolution was critical to identifying
pICL1 as a 2nd metabolic engineering target, which would have
been discarded if selected based on intuition.
The approach employed represents an integration of diverse
methods for rapid metabolic engineering proof-of-concept. The
strain selection process thus need not be limited to considering
organisms showing a predisposition to the production of the
metabolite of interest, but rather, should include hosts most
suitable for large-scale, robust, and biorefinery processing. With
such hosts, carbon and redox flux redistribution requiring multi-
gene approaches can be predicted, tested, and supplemented with
directed evolution, screening, and selection. These strains are then
transcriptionally characterized and optimized until commercially
viable titers, productivities, and yields are reached. It is only
through whole-process optimization and elimination of severe
constraints such as forced use of non-industrially favorable strains,
that the promise of a bio-based economy may be fully realized.
Materials and Methods
Strain Construction
The reference strain Saccharomyces cerevisiae CEN.PK113-5D (Mat
a MAL2-8C SUC2 URA3-52) [30] was used for the construction of
the Dsdh3 Dser3 Dser33 knockout strain, referred to as the 8D
mutant, and for the construction of the Dsdh3 Dser3 Dthr1 knockout
strain, referred to as the 20G mutant, through the cloning-free
PCR-based allele replacement method previously described [31].
The upstream SDH3 fragment was amplified by PCR from
genomic DNA using the primers SDH3_Up_Fw (sequence 59-
CGAAATATGGTAAGAGAAAATG-39) and SDH3_Up_Rv (se-
quence 59- CAGGGATGCGGCCGCTGACGACATCG
TTTATTATTCTTAGAGC-39). Similarly, the downstream
SDH3 fragment was amplified using the primers SDH3 _Dw_Fw
(sequence 59- CCGCTGCTAGGCGCGCCGTGCTTTAT-
GATTCTTTAAGGCGACGC-39) and SDH3_Dw_Rv (sequence
59- GTAATCTGTTATCGATAATCTGCC -39). The upstream
THR1 fragment was amplified by PCR from genomic DNA using
the primers THR1_Up_Fw (sequence 59-GCAGTTC
TTGCTCAGTAATCTTAG-39) and THR1_Up_Rv (sequence
59-GCAGGGATGCGGCCGCTGACCCATA TCTTTCGA-
GATGATGACTC-39). Similarly, the downstream THR1 frag-
ment was amplified using the primers THR1 _Dw_Fw (sequence
59-CCGCTGCTAGGCGCGCCGTGCATACTGTAATT-
GACCGTTAACGG-39) and THR1_Dw_Rv (sequence 59-
CCAATCATGGATGAACCAGTAATG-39). The upstream
SER3 fragment was amplified by PCR from genomic DNA using
the primers SER3_Up_Fw (sequence 59- CTCACAATCGAG-
TAA TGCCTTTG-39) and SER3_Up_Rv (sequence 59-
GCAGGGATGCGGCCGCTGACCATTGCTGTCGA
TTTTTCTGTGG-39). Similarly, the downstream SER3 fragment
was amplified using the primers SER3 _Dw_Fw (sequence 59-
CCGCTGCTAGGCGCGCCGTGGGATAGAAGAATGCTT-
GAGGC-39) and SER3_Dw_Rv (sequence 59- CGAATTT-
GATTGTACCTGGTGC-39). The upstream SER33 fragment
was amplified by PCR from genomic DNA using the primers
SER33_Up_Fw (sequence 59- GTACTCTTTATGG-
GAGTCTTTAGC -39) and SER33_Up_Rv (sequence 59-
GCAGGGATGCGGCCGCTGACGCAGCTGAATAAGA-
CATGTTAGG- 39). Similarly, the downstream SER33 fragment
was amplified using the primers SER33 _Dw_Fw (sequence 59-
GCAGGGATGCGGCCGCTGACGCAGCTGAATAAGA-
CATGTTAGG- 39) and SER33_Dw_Rv (sequence 59-CTATT
CTGGGTGGTCTTTTACTGG- 39). The lithium acetate tran-
formation method was used [32]. As described previously, URA3
from Kluyvermyces lactis was used as the selection marker in the
transformation process [31]. With this approach tranformants are
easily selected on uracil depleted media supplemented with 5-
fluoroorotic acid. The knockout was confirmed by restriction
analysis followed by sequencing (MWG Biotech AG, Ebersberg,
Germany).
The plasmid pRS426T-ICL1-C was constructed and trans-
formed into 8D Evolved, described earlier and used for
constitutive S. cerevisiae ICL1 overexpression. The parent plasmid,
pRS426CT (6347 bp), was previously constructed in our labora-
tory by inserting the strong constitutive TEF1 promoter (gene
encoding S. cerevisiae translation-elongation factor 1a) and the
CYC1 transcription terminator into pRS426 [28]. This original
backbone plasmid is a 5726 bp yeast episomal plasmid (YEp)-type
shuttle vector with a high copy number of about 20 per cell [33].
The plasmid contains the 2 mm ori and pUC ori for independent
episomal replication in S. cerevisiae and E. coli, respectively, and
URA3 and ampR (bla, beta-lactamase) genes. The final plasmid size
was 8074 bp, with 2484 containing the TEF1 promoter, the ICL1
insert, and the CYC1 transcription terminator sequence, verified by
sequencing (MWG Biotech AG, Ebersberg, Germany).
A total of eight primers were required for amplification of the
native ICL1 gene from the reference strain, sequencing of the
constructed plasmid pRS426-ICL1-C, and PCR to verify plasmid
presence in the transformed reference and 8D Evolved strains
(referred to as 8D Evolved with pICL1). The PCR amplification of
ICL1 was carried out using the PhusionTM High-Fidelity DNA
Polymerase (Finnzymes Oy, Espoo, Finland) according to the
manufacturer’s protocol. The native ICL1 was amplified from
genomic DNA using the up- and downstream primers ICL1_Sp1
(sequence 59-GCCTGCCA|CTAGTCAACGAAAAATGCC-
TATCCCCG-39), and ICL1_Asp1 (sequence 59-
GCCTCGACCCGGGCTAGAGAAAGGCATTCTTG-
CACGG-39 ), respectively. The amplicon length was 1915 bp.
The fragment was cut with restriction endonucleases (REN) SpeI,
the restriction site of which was de novo introduced on primer
ICL1_Sp1, and NgoMIV, and then ligated with pRS426CT cut
with SpeI and XmaI. By using the non-compatible RENs in either
end of the insertion, the direction of the insert is secured and
furthermore the sole parent plasmid Xma site is lost. This allowed
for an in vitro pre-selection for the correct pRS426-ICL1-C
construct prior to transformation.
The four sequencing primers for construct verification included
M13_rev_-29 (sequence 59-CAGGAAACAGCTATGACC-39),
ICL1_In_1f (sequence 59-CTGGTTGGCAGTGTTCATCA-39),
ICL1_In_2f (sequence 59-CATCCCACAGAGAAGCCAAG-39),
and M13_uni_-21 (sequence 59-TGTAAAACGACGGCCAGT-
39). The two primers used for plasmid verification via PCR (Taq
DNA Polymerase of Thermus aquaticus from Sigma, St. Louis, MO,
were ICL1_part_Sense (sequence 59-TCCTGTTCAGATTTCT-
CAAATGGC-39) and ICL1_CYC_Antisense (sequence 59-
AAATTAAAGCCTTCGAGCGTCCC-39) and these were used
for analytical PCRs according to the instruction manual’s
recommendations). Plasmid transformation of electrocompetent
E. coli DH5a were completed as described previously, as was
plasmid transformation of the S. cerevisiae reference strain and 8D
Evolved using the lithium acetate method [28], [31], [32].
Medium Formulation
A chemically defined minimal medium of composition 5.0 g
L21 (NH4)2SO4, 3.0 g L
21 KH2PO4, 0.5 g L
21 MgSO4N7H2O,
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1.0 mL L21 trace metal solution, 300 mg L21 uracil, 0.05 g L21
antifoam 204 (Sigma-Aldrich A-8311), and 1.0 mL L21 vitamin
solution was used for all shake flask and 2L well-controlled
fermentations [34]. The trace elment solution included 15 g L21
EDTA, 0.45 g L21 CaCl2N2H2O, 0.45 g L
21 ZnSO4 N7H2O,
0.3 g L21 FeSO4N7H2O, 100 mg L
21 H3BO4, 1 g L
21
MnCl2N2H2O, 0.3 g L
21 CoCl2N6H2O, 0.3 g L
21 CuSO4N5H2O,
0.4 g L21 NaMoO4N2H2O. The pH of the trace metal solution
was adjusted to 4.00 with 2 M NaOH and heat sterilized. The
vitamin solution included 50 mg L21 d-biotin, 200 mg L21 para-
amino benzoic acid, 1 g L21 nicotinic acid, 1 g L21 CaNpantothe-
nate, 1 g L21 pyridoxine HCl, 1 g L21 thiamine HCl, and 25 mg
L21 mNinositol. The pH of the vitamin solution was adjusted to 6.5
with 2 M NaOH, sterile-filtered and the solution was stored at
4uC. The final formulated medium, excluding glucose and vitamin
solution supplementation, is adjusted to pH 5.0 with 2 M NaOH
and heat sterilized. For carbon-limited cultivations the sterilized
medium is supplemented with 20 g L21 glucose, heat sterilized
separately, and 1.0 mL L21 vitamin solution is added by sterile
filtration (0.20 mm pore size MinistartH-Plus Sartorius AG,
Goettingen, Germany). For cultures where glycine or threonine
auxotrophic strains were cultivated the final culture medium was
supplemented with glycine 500 mg L21 or 100 mg L21 threonine
added by sterile filtration.
Shake Flask Cultivations and Stirred Tank Fermentations
Shake flask cultivations were completed in 500 mL Erlenmeyer
flasks with two diametrically opposed baffles and two side-necks
with septums for sampling by syringe. Flasks were heat sterilized
with 100 mL of medium, inoculated with a single colony, and
incubated at 30uC with orbital shaking at 150 RPM. Stirred tank
fermentations were completed in well-controlled, aerobic, 2.2L
Braun Biotech Biostat B fermentation systems with a working
volume of 2L (Sartorius AG, Goettingen, Germany). The
temperature was controlled at 30uC. The fermenters were
outfitted with two disk-turbine impellers rotating at 600 RPM.
Dissolved oxygen was monitored with an autoclavable polaro-
graphic oxygen electrode (Mettler-Toledo, Columbus, OH).
During aerobic cultivation the air sparging flow rate was 2 vvm.
The pH was kept constant at 5.0 by automatic addition of 2 M
KOH. Off-gas passed through a condenser to minimize the
evaporation from the fermenter. The fermenters were inoculated
from shake flask precultures to an initial OD600 0.01.
Fermentation Analysis
Off-gas Analysis. The effluent fermentation gas was mea-
sured every 30 seconds for determination of O2(g) and CO2(g)
concentrations by the off-gas analyzer Bru¨el and Kjær 1308 (Bru¨el
& Kjær, Nærum, Denmark).
Biomass Determination. The optical density (OD) was
determined at 600 nm using a Shimadzu UV mini 1240
spectrophotometer (Shidmazu Europe GmbH, Duisberg, Ger-
many). Duplicate samples were diluted with deionized water to
obtain OD600 measurements in the linear range of 0–0.4 OD600
Samples were always maintained at 4uC post-sampling until
OD600 and dry cell weight (DCW) measurements were performed.
DCW measurements were determined through the exponential
phase, until stationary phase was confirmed according to OD600
and off-gas analysis. Nitrocellulose filters (0.45 mm Sartorius AG,
Goettingen, Germany) were used. The filters were pre-dried in
a microwave oven at 150W for 10 min., and cooled in a dessicator
for 10 min. 5.0 mL of fermentation broth were filtered, followed
by 10 mL DI water. Filters were then dried in a microwave oven
for 20 min. at 150W, cooled for 15 min. in a desiccator, and the
mass was determined.
Metabolite Concentration Determination. All fermenta-
tion samples were immediately filtered using a 0.45 mm syringe-
filter (Sartorius AG, Goettingen, Germany) and stored at 220uC
until further analysis. Glucose, ethanol, glycerol, acetate, succi-
nate, pyruvate, fumarate, citrate, oxalate, and malate were
determined by HPLC analysis using an Aminex HPX-87H ion-
exclusion column (Bio-Rad Laboratories, Hercules, CA). The
column was maintained at 65uC and elution performed using
5 mM H2SO4 as the mobile phase at a flow rate of 0.6 mL min.
21. Glucose, ethanol, glycerol, acetate, succinate, citrate, fumarate,
malate, oxalate were detected on a Waters 410 differential
refractometer detecter (Shodex, Kawasaki, Japan), and acetate
and pyruvate were detected on a Waters 468 absorbance detector
set at 210 nm.
Transcriptomics
RNA Sampling and Isolation. Samples for RNA isolation
from the late-exponential phase of glucose-limited batch cultiva-
tions were taken by rapidly sampling 25 mL of culture into
a 50 mL sterile Falcon tube with 40 mL of crushed ice in order to
decrease the sample temperature to below 2uC in less than 10
seconds. Cells were immediately centrifuged (4000 RPM at 0uC
for 2.5 min.), the supernatant discarded, and the pellet frozen in
liquid nitrogen and it was stored at 280uC until total RNA
extraction. Total RNA was extracted using the FastRNA Pro RED
kit (QBiogene, Carlsbad, USA) according to manufacturer’s
instructions after partially thawing the samples on ice. RNA
sample integrity and quality was determined prior to hybridization
with an Agilent 2100 Bioanalyzer and RNA 6000 Nano LabChip
kit according to the manufacturer’s instruction (Agilent, Santa
Clara, CA).
Probe Preparation and Hybridization to DNA
Microarrays. Messenger RNA (mRNA) extraction, cDNA
synthesis, labeling, and array hybridization to Affymetrix Yeast
Genome Y2.0 arrays were performed according to the manufac-
turer’s recommendations (Affymetrix GeneChipH Expression
Analysis Technical Manual, 2005–2006 Rev. 2.0). Washing and
staining of arrays were performed using the GeneChip Fluidics
Station 450 and scanning with the Affymetrix GeneArray Scanner
(Affymetrix, Santa Clara, CA).
Microarray Gene Transcription Analysis. Affymetrix
Microarray Suite v5.0 was used to generate CEL files of the
scanned DNA microarrays. These CEL files were then processed
using the statistical language and environment R v5.3 (R
Development Core Team, 2007, www.r-project.org), supplemen-
ted with Bioconductor v2.3 (Biconductor Development Core
Team, 2008, www.bioconductor.org) packages Biobase, affy,
gcrma, and limma [35], [36]. The probe intensities were
normalized for background using the robust multiarray average
(RMA) method only using perfect match (PM) probes after the raw
image file of the DNA microarray was visually inspected for
acceptable quality. Normalization was performed using the qspline
method and gene expression values were calculated from PM
probes with the median polish summary. Statistical analysis was
applied to determine differentially expressed genes using the
limma statistical package. Moderated t-tests between the sets of
experiments were used for pair-wise comparisons. Emperical
Bayesian statistics were used to moderate the standard errors
within each gene and Benjamini-Hochberg’s method was used to
adjust for multi-testing. A cut-off value of adjusted p,0.05 was
used for statistical significance. Furthermore, principal component
analysis (PCA) was performed in order to elucidate the relative
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importance of substrate limitation (carbon vs. nitrogen) and
growth rate (0.03 h21, 0.1 h21, 0.2 h21), previously described
[21], when compared with the gene expression of the reference
and 8D Evolved strain. To select genes whose expression levels
were related to these factors, the moderated t-statistics were
followed up with F-distributions to yield a statistic referred to as Fg,
which is simply the usual F-statistic from linear model theory but
with the posterior variance substituted for the sample variance in
the denominator, as described else where [35]. The cut-off value of
adjusted p,0.1 was used for statistical significance.
All microarray data is MIAME compliant and the raw data has
been deposited in ArrayExpress (http://www.ebi.ac.uk/
microarray-as/ae/).
Supporting Information
Figure S1 Inhibition of the succinate dehydrogenase
complex with malonate supplementation in shake flask
cultures was evaluated. The reference and Dsdh3 strain,
previously described [17], were cultured in minimal media
supplemented with 10 g L21 glucose and no succinate accumu-
lation was detected (Panel a). The reference strain was cultured
with 0.1, 1.0, 5.0, 10.0, and 50.0 mM malonate supplementation.
Under no supplementation conditions succinate accumulation was
observed (Panel b). In order to confirm that the concentration of
malonate in the culture was effectively inhibiting succinate
dehydrogenase activity, residual ethanol in the culture broth was
monitored. Succinate dehydrogenase activity, as previously de-
scribed, catalyzes the conversion of succinate to fumarate with net
production of protonated ubquinone. Ethanol is a carbon source
readily catabolized by S. cerevisiae using respiro-fermentative
pathways and requiring succinate dehydrogenase activity. Panel
c shows the residual glucose concentration in the culture broth at
0, 17, 22, and 37h post-inoculation for no supplementation of
malonate (reference) and then 0.1, 1.0, 5.0, 10.0, and 50.0 mM
malonate supplementation. These growth profiles were generated
using the reference strain (CEN.PK113-7D). As expected, full
catabolism of glucose was observed at all malonate concentrations
with the exception of 50.0 mM, thereby considered an upper limit.
Similarly, in panel d, is the ethanol concentration in the culture
broth for the same malonate concentrations and sample times. At
37 h, as expected, the reference strain had consumed nearly all
ethanol produced during the glucose consumption phase.
Malonate concentrations of 1.0, 5.0, and 10.0 mM malonate
resulted in significant ethanol respiration inhibition compared to
no supplementation and 0.1 mM malonate, confirming that
respiro-fermentative catabolism was inhibited. Under no circum-
stances was succinate accumulation observed. Furthermore, the
Dsdh3 strain was supplemented with 50.0 mM malonate to ensure
no unexpected interaction between the genetic modification and
malonate supplementation (panel e).
(PNG)
Figure S2 A total of 1964 genes were submitted to the
Saccharomyces Genome Database tool, Pathway Ex-
pression Viewer. The resulting Pathway Expression map shows
the relative log-fold change of all S. cerevisiae metabolic reactions
(Evolved 8D vs. Reference). Three key results are high-lighted
from the transcriptome. First, isocitrate lyase (ICL1) was amongst
the few genes not up-regulated in the Evolved 8D strain, thereby
becoming a 2nd round metabolic engineering target. Second,
alanine:glyoxylate aminotransferase (AGX1) was 4.3 log-fold higher
in the Evolved 8D strain, confirming the predicted model-guided
strategy of up-regulated glycine formation from glyoxylate pools.
Third, threonine aldolase (GLY1) was 1.6 log-fold higher in the
Evolved 8D strain. The genome-scale model reconstruction used
for predictions annotated Gly1p as catalyzing the reversible
conversion of threonine to glycine. This reaction has since been
shown to be irreversible, converting threonine to glycine,
consuming equimolar acetaldehyde. The transcriptome data
suggests that the Evolved 8D strain demonstrated de-coupling of
succinate and biomass production because alternative reactions
(e.g., Gly1p) were supplying glycine pools.
(PNG)
Figure S3 Panel a briefly describes the mutant con-
struction of 20G, Dsdh3 Dser3 Dthr1, from the reference
strain and initially supplemented with 100 mg L21
threonine and 500 mg L21 glycine to satisfy the resulting
auxotrophies. All growth challenges were evaluated in shake
flasks supplemented with minimal medium, 300 mg L21 uracil,
10 g L21 glucose, and either threonine and/or glycine added, as
indicated. The mutant 20G was not capable of sustaining growth
in the absence of threonine, and therefore a working cell bank was
prepared. Panel b describes the shake flask experiments and
progression followed to evaluate the strain’s ability to be evolved
from threonine supplementation to glycine supplementation.
When 20G culture was inoculated from threonine supplemented
medium to glycine only supplemented medium, no growth was
observed up to 14d post-inoculation (2 samples per day measuring
OD600). On day 14, a shake flask culture of 20G only
supplemented with glycine, was then supplemented with 100 mg
L21 threonine, and growth was immediately restored. It was
therefore concluded that the mutant 20G was incapable of
catalyzing glycine to threonine to satisfy threonine cellular
demands, given that threonine synthesis was interrupted with the
deletion of thr1. This experimental conclusion further supports that
Gly1 encoding threonine aldolase, originally believed to catalyze
the conversion of glycine to threonine, catalyzes the reverse
reaction and thus cannot meet threonine cellular demands from
glycine pools.
(PNG)
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